Back to Search
Start Over
Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a
- Source :
- The World Allergy Organization Journal
- Publication Year :
- 2019
-
Abstract
- Background Omalizumab has demonstrated efficacy as an add-on therapy in Chinese patients with moderate-to-severe allergic asthma. This post-hoc analysis assessed the potential predictors for the efficacy of omalizumab in these patients. Methods A post-hoc analysis was performed on a Phase III, randomised, controlled study conducted in Chinese patients with moderate-to-severe persistent allergic asthma (NCT01202903). We evaluated if levels of pre-treatment serum total immunoglobulin-E (IgE) and blood eosinophil (EOS), asthma severity, allergen profile, history of perennial allergic rhinitis (PAR), and free IgE level during omalizumab treatment were predictive of omalizumab's efficacy. Results This analysis included 608 patients (omalizumab, N = 306; placebo, N = 302). Improvements in forced expiratory volume in 1 s (FEV1), standardized Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Questionnaire (ACQ), and Global Evaluation of Treatment Effectiveness (GETE) scores with omalizumab treatment compared with placebo were observed in patients with baseline IgE levels ≥76 IU/mL (irrespective of the EOS count). Relatively greater improvements with omalizumab treatment was also noted in patients with both moderate or severe allergic asthma (regardless of asthma severity), and patients sensitised to >3 allergens and with a history of PAR. All patients who were treated with omalizumab achieved free IgE levels below 50 ng/mL by Week 1. Similar clinical outcomes were observed in the subset of patients who achieved free IgE levels of
- Subjects :
- China
EOS, Eosinophil
IgE, Immunoglobulin-E
FAS, Full analysis set
LSM-TD, Least squares mean treatment differences
IL-5, Interleukin-5
Omalizumab
AQLQ, Asthma Quality of Life Questionnaire
Article
ACQ, Asthma Control Questionnaire
PK, Pharmacokinetic
Allergic
QoL, Quality of life
PEF, Peak expiratory flow
RAST, Radio-allergosorbent test
ULOQ, Upper limit of quantification
OMA, Omalizumab
PAR, Perennial allergic rhinitis
ICS, Inhaled corticosteroid
LSM, Least squares mean
RMU, Rescue medication use
Immunoglobulin E
ANCOVA, Analysis of covariance
SAR, Seasonal allergic rhinitis
Asthma
LABA, Long-acting β agonist
PBO, Placebo
Eosinophils
PD, Pharmacodynamics
GETE, Global Evaluation of Treatment Effectiveness
FEV1, Forced expiratory volume in 1 s
FCεR1, High affinity IgE binding receptor 1
CMH, Cochran-Mantel-Haenszel
Subjects
Details
- ISSN :
- 19394551
- Volume :
- 13
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- The World Allergy Organization journal
- Accession number :
- edsair.pmid..........ce729121e2360d54b106f0a865e17511